Inozyme Pharma, Inc.

États‑Unis d’Amérique

Commandez votre montre hebdomadaire Inozyme Pharma, Inc.
Quantité totale PI 49
Rang # Quantité totale PI 28 749
Note d'activité PI 2,5/5.0    37
Rang # Activité PI 20 288
Symbole boursier INZY (nasdaq)
ISIN US45790W1080
Capitalisation 165M  (USD)
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

17 3
12 2
10 3
2
 
Dernier brevet 2025 - Treatment of enpp1 deficiency an...
Premier brevet 2011 - Npp1 fusion proteins
Dernière marque 2025 - ENLANPPI
Première marque 2018 - INOZYME

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and diso...
P/S Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disor...
2024 Invention Treatment of enpp1 deficiency and abcc6 deficiency. The present disclosure provides, among other...
Invention Methods of improving cardiovascular function and treating cardiovascular disease using a recombin...
Invention Treatment of enpp1 deficiency and abcc6 deficiency in children. in vivoin vivo treatment of an EN...
Invention Lyophilized enpp1 polypeptide formulations and uses thereof. In certain aspects, the present inv...
2023 Invention Liver specific production of enpp1 or enpp3. The present disclosure provides, among other things...
Invention Treatment of enpp1 deficiency and abcc6 deficiency. The present disclosure provides, among other ...
2022 Invention Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome...
Invention Compositions and methods for treating peripheral artery disease. The present disclosure provides...
Invention Compositions and methods for inhibiting vascular smooth muscle cell proliferation. The present d...
Invention Lyophilized enpp1 polypeptide formulations and uses thereof. In certain aspects, the present inve...
Invention Treatment of diseases involving deficiency of enpp1 or enpp3. The present disclosure provides, a...
Invention Npp1 fusion proteins. The present invention provides a novel fusion polypeptide containing a cat...
Invention Methods of treating myointimal proliferation. The present invention provides a method of treatin...
2021 Invention Liver specific production of enpp1 or enpp3. in vivoin vivo and methods for the treatment of dise...
P/S Pharmaceutical preparations for the diagnosis and therapeutic treatment of bone and kidney diseas...
P/S Pharmaceutical preparations for the diagnosis and therapeutic treatment of diseases or disorders...
Invention Soluble enpp1 or enpp3 proteins and uses thereof. In certain aspects, the present invention provi...
Invention Compositions and methods for treating peripheral artery disease. The present disclosure provides ...
Invention Compositions and methods for inhibiting vascular smooth muscle cell proliferation. The present di...
2020 P/S therapeutic pharmaceutical for the diagnosis and treatment of diseases or disorders afflicting th...
P/S Pharmaceutical preparations; diagnostic preparations for medical purposes; none of the aforesaid ...
Invention Treatment of diseases involving deficiency of enpp1 or enpp3. in vivo in vivo and methods for the...
2018 P/S Pharmaceutical preparations, in particular therapeutic pharmaceuticals for the diagnosis and trea...
P/S Pharmaceutical preparations and substances for use in the diagnosis and treatment of bone disease...
2017 Invention Methods of treating tissue calcification. The present invention provides a method of treating NPP...
Invention Methods of treating myointimal proliferation. The present invention provides a method of treating...
2014 Invention Npp1 fusion proteins. The present invention provides a novel fusion polypeptide containing a cata...